Primary infection of pregnant ewes with Toxoplasma gondii leads to abortion and significant economic losses for the livestock industry. Moreover, infected animals constitute the main parasitic reservoir for humans, since the meat is commonly eaten undercooked. Therefore, the development of a one-health vaccine seems the best prevention strategy. A vaccine constituted of total extract (TE) of Toxoplasma gondii proteins incorporated into biodegradable maltodextrin-based nanoparticles (DGNP) has been developed. This DGNP/TE platform induces specific Th1/Th17 cellular immune responses and vaccination led to 100% survival of mice with acute toxoplasmosis and to significant reduction in the number of brain cysts of mice with chronic toxoplasmosis or of offspring born to immunized mice infected during pregnancy (1). In ewes, immunization with DGNP/TE vaccine generated specific Th1-cellular immune response (2). No cerebral cyst could be detected in ewes after infection with T. gondii and vertical transmission of the parasite to lambs was drastically reduced (88%). Thus, DGNP/TE vaccine administered by the nasal route conferred a high level of protection against latent toxoplasmosis and its transplacental transmission in sheep, highlighting the potential for development of such a vaccine for studies in other species.